Development of non-Hodgkin lymphoma as a second primary cancer in hepatitis C virus-infected patients with a different primary malignancy
Minas P. Economides(NYU Langone Health), Harrys A. Torres(The University of Texas MD Anderson Cancer Center), Bruno Granwehr(The University of Texas MD Anderson Cancer Center), Jeff Hosry(The University of Texas MD Anderson Cancer Center), Felipe Samaniego(The University of Texas MD Anderson Cancer Center), Parag Mahale(National Cancer Institute), Francesco Turturro(The University of Texas MD Anderson Cancer Center)
Cited by 6
Related Papers
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
|Nature Medicine|2020|593
Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experience
|British Journal of Haematology|2014|364
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
|The Lancet Oncology|2014|263